Robeauté sits at the access-and-delivery layer of neurotech, its microrobot is a carrier designed to reach brain targets other technologies can't, with biopsy as the first application and electrode implantation or drug delivery as future payloads. One of Europe's largest medtech seed rounds ($28M) and a strategic Brainlab investment give it capital and distribution weight ahead of its first human trials, planned for 2027.